F093 Red Flags and Emergencies in Dermatology
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
It is often believed that dermatology does not involve life-threatening situations, with many observers considering skin disorders as being only “skin deep” and of no more than aesthetic/cosmetic importance. The truth is that the dermatology unit is no stranger to life-threatening skin diseases or serious and lethal systemic diseases with cutaneous manifestations. Moreover, dermatologists are not spared the possibility of needing to deal with severely sick patients. Indeed, dermatologists are frequently the first physicians to examine a patient, thus becoming responsible for making the initial diagnosis of grave conditions that require urgent attention. The present session will provide descriptions of a selection of acute, severe, life-threatening skin diseases, with the aim of guiding dermatologists in rapid and accurate diagnostic decision-making, and be better able to carry out the appropriate urgent interventions, for these conditions.
LEARNING OBJECTIVES
Diagnose acute life-threatening skin diseases or serious and lethal systemic diseases with cutaneous manifestations.
Identify critical dermatological situations, recognize red flags that signal real emergencies, and differentiate them from everyday skin ailments that do not pose any immediate danger or emergency.
Describe the pathological aspects of life-threatening skin diseases, better able to carry out the appropriate urgent interventions, and be well-informed about the most up-to-date treatments available for these conditions.
SCHEDULE
5:00 PM
Introduction
Warren R. Heymann, MD, FAAD
5:05 PM
Eschars: Signs of Life-threatening Disorders
Theodore Rosen, MD, FAAD
5:25 PM
Q&A
Theodore Rosen, MD, FAAD
5:30 PM
Life-threatening Stings, Bites, and Marine Envenomation
Dirk Michael Elston, MD, FAAD
5:50 PM
Q&A
Dirk Michael Elston, MD, FAAD
5:55 PM
Dermatological Urgent Care: When Banalities Surprise You
Warren R. Heymann, MD, FAAD
6:15 PM
Q&A
Warren R. Heymann, MD, FAAD
6:20 PM
Use of Biologic Agents and Immunomodulators in Cutaneous Emergencies
Mark Lebwohl, MD, FAAD
6:40 PM
Q&A
Mark Lebwohl, MD, FAAD
SPEAKERS
Dirk Michael Elston, MD, FAAD
Warren R. Heymann, MD, FAAD
Mark Lebwohl, MD, FAAD
Theodore Rosen, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Dirk Michael Elston, MD, FAAD
No financial relationships exist with ineligible companies.
Warren R. Heymann, MD, FAAD
No financial relationships exist with ineligible companies.
Mark Lebwohl, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Aikium – Consultant (1099 relationship)(Honoraria); Almirall – Consultant(Honoraria); AltruBio Inc. – Consultant(Honoraria); Amgen – Consultant (1099 relationship)(Honoraria); Apogee Therapeutics – Consultant(Honoraria); Arcutis, Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); AstraZeneca – Consultant (1099 relationship)(Honoraria); Atomwise – Consultant(Honoraria); Avotres, Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Honoraria), Investigator(Grants/Research Funding); Bristol-Myers Squibb – Consultant(Honoraria); Cara Therapeutics – Investigator(Grants/Research Funding); Castle Biosciences, Inc – Consultant(Honoraria); Celltrion – Consultant(Honoraria); Clexio Biosciences, Ltd – Investigator(Grants/Research Funding); CoreEvitas, LLC – Consultant(Honoraria); Dermavant Sciences – Consultant(Honoraria), Investigator(Grants/Research Funding); Dermsquared – Consultant (1099 relationship)(Honoraria); Eli Lilly and Company – Investigator(Grants/Research Funding); Evommune, Inc. – Consultant(Honoraria); Facilitation of International Dermatology Education – Consultant(Honoraria); Forte Biosciences – Consultant(Honoraria); Galderma – Consultant(Honoraria); Genentech, Inc. – Consultant(Honoraria); Incyte Corporation – Consultant(Honoraria), Investigator(Grants/Research Funding); Inozyme Pharma – Investigator(Grants/Research Funding); Janssen Research & Development, LLC – Investigator(Grants/Research Funding); Leo Pharma A/S – Consultant(Honoraria); Mayne Pharma Group – Consultant (1099 relationship)(Honoraria); Meiji Seika Pharma Co., Ltd – Consultant(Honoraria); Mindera – Consultant(Honoraria); Mirum Pharmaceuticals, Inc. – Consultant (1099 relationship)(Honoraria); New York College of Podiatric Medicine – Speaker/Faculty Education(Honoraria); Oruka Therapeutics – Consultant (1099 relationship)(Honoraria); Pfizer Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); Revolo Therapeutics – Consultant (1099 relationship)(Honoraria); Sanofi/Regeneron – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Seanergy Maritime Holdings Corp. – Consultant(Honoraria); Strata Skin Sciences – Consultant(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Honoraria); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Honoraria); Trevi Therapeutics – Consultant(Honoraria); UCB – Investigator(Grants/Research Funding); Verrica Pharmaceuticals Inc – Consultant(Honoraria);
Theodore Rosen, MD, FAAD
No financial relationships exist with ineligible companies.